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Abstract [3Hl9-Methyl-7-bromoeudistomin D ([3HIMBED), 
the most powerful Ca 2+ releaser from sarcoplasmic reticulum, 
specifically bound to the brain microsomes. Caffeine competi- 
tively inhibited [3H]MBED binding. [3H]MBED binding was 
markedly blocked by procaine, whereas that was enhanced by 
adenosine-5'-(~,y-methylene)triphosphate. The Bma x value was 
170 times more than that of [3HIryanodine binding. The profile 
of sucrose-density gradient centrifugation of solubilized micro- 
somes indicated that [3H]MBED binding protein was different 
from [3HIryanodine binding protein. These results suggest hat 
there are MBED/caffeine~binding sites in brain that are distinct 
from the ryanodine receptor and that MBED becomes an essen- 
tial molecular probe for characterizing caffeine-binding protein 
in the central nervous system. 
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1. Introduction 
Pharmacological ctions of caffeine have been extensively 
studied by numerous investigators because ithas many interest- 
ing actions on the central nervous ystem including analeptic 
and analgesic effects [1]. One of the most important pharmacol- 
ogical actions of caffeine is related to calcium movements. In
neuronal tissues, release of stored Ca 2+ from endoplasmic retic- 
ulum (ER) triggers several physiological processes including 
neutrotransmitter r lease [2] and changes in the cytoskeleton 
[3]. Although Ca 2÷ release from the store has been well charac- 
terized with inositol 1,4,5-trisphosphate (IP3), one of the most 
important second messengers [4-7], the presence of IP3-re- 
sistant Ca 2+ stores has been suggested [8-11]. The Ca2+-induced 
Ca 2÷ release (CICR) channel is a possible candidate for the 
pathway of Ca 2+ release from the IP3-resistant Ca 2+ stores and 
has been identified as the [3H]ryanodine r ceptor in brain [12- 
15]. Caffeine triggers Ca > release from not only sarcoplasmic 
reticulum (SR) but also from ER and through CICR channels 
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CICR, Ca 2* induced Ca 2÷ release; HEPES, 2[4-(2-hydroxyethyl)-l-pi- 
perazinyl]ethanesulfonic acid; AMPPCP, adenosine-5'-(fl, y-meth- 
ylene)triphosphate; PKG, cyclic GMP-dependent protein kinase. 
[16-21]. However, direct binding studies of caffeine have been 
impossible because of its low affinity. Natural bioaetive sub- 
stances uch as ryanodine have been essential as biochemical 
tools for characterizing and purifying functional proteins 
[22-26]. It has been reported that 9-methyl-7-bromoeudistomin 
D (MBED), a derivative of eudistomin D isolated from the 
Caribbean tunicate Eudistoma olivaeeum, having caffeine-like 
properties, powerfully induces Ca > release from SR in skeletal 
muscle [27,28]. Recently, we have successfully synthesized 3H- 
labeled MBED with a high specific radioactivity and revealed 
the properties of MBED binding sites [29]. [3H]MBED interacts 
competitively with caffeine in binding at the same site on the 
skeletal muscle Ca2+-release channels (ryanodine r ceptor). The 
site differs from the ryanodine-, adenine nucleotide- or Ca >- 
binding site on the same receptor [29-3 l]. In the central nervous 
system, we have more recently found that MBED exhibits 
effects similar to that of caffeine (S. Kaneko, T. Tadano, 
K. Matsunaga, K. Kisara and Y. Ohizumi, unpublished ob- 
servation). In this paper we successfully characterized the 
caffeine-binding sites in mammalian brain using [3H]MBED as 
a specific ligand for the caffeine-binding site for the first time. 
[3H]MBED has become an essential tool not only for stud- 
ying caffeine-binding sites but also for Ca2+-release channels in 
SR/ER. 
2. Materials and methods 
Guinea pig whole brain without he brainstem or dissected brain 
regions were homogenized in Buffer A containing 0.32 M sucrose, 
10 mM 2-[4-(2-hydroxyethyl)-l-piperazinyl]ethanesulfonic acid 
(HEPES)/Tris (pH 7.6), 10 mM EGTA and protein inhibitors (100/aM 
p-aminophenylmethylsulfonylfluoride, 0.5 mg/ml aprotinin, 0.5 ng/ml 
leupeptin, 0.83 mM benzamidine). Homogenates were centrifuged twice 
at 11,000 x g for 20 min, and supernatants were centrifuged at 
100,000 x g for 60 rain. Pellets were resuspended in Buffer A and 
freezed with liquid nitrogen and stored at -80°C. These procedures 
were carried out below 4°C. Protein was assayed by the modified 
Lowry method [32] with bovine serum albumin as a standard. 
Brain microsomes were suspended at5 mg of protein/ml in Buffer B 
containing 2.5 % 3 -[(3 -cholamidopropyl)dimethylammonio)- 1 -pro pane- 
sulfonate (CHAPS), 1% phosphatidylcholine, 1 M NaC1, 20 mM Tris- 
HC1 (pH 7.4). After 90 min of gentle stirring at 4°C, the mixture was 
centrifuged for 30 min at 310,000 x g and supernatant was collected as 
the CHAPS-solubilized sample. 
The CHAPS-solubilized sample was layered onto a 8 ml linear den- 
sity gradient of sucrose (5 20%) in buffer containing 1.25% CHAPS, 
0.5% phosphatidylcholine, 50 mM NaC1, 20 mM Tris-HCl (pH 7.4) and 
centrifuged for 16 h in a Beckman SW-41 rotor at 100,000 x g using 
slow acceleration a d deceleration profiles. After centrifugation, each 
fraction (1 ml) was collected from the top, then diluted with water to 
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decrease the concentration f sucrose below 0.32 M, and then sedi- 
mented by centrifugation for 90 min in a Beckman Ty-42.1 rotor at 
100,000 x g. Pellets were resuspended in Buffer B. 
3H-labeled MBED was synthesized byN-methylation f6-O-acetyl- 
bromoeudistomin D with [3H]methyl iodide, followed by deacethyla- 
tion as reported previously [28,33]. The labeled MBED was purified by 
reversed phase and silica gel thin-layer chromatography. The specific 
radioactivity was 10.2 Ci/rnmol. 
Brain microsomes or solubilized samples (0.02-0.2 mg/ml) were incu- 
b~ted with 5-70 nM [3H]MBED at 0°C or 2-30 nM [3H]ryanodine (Du 
P, rot-New England Nuclear) at 37°C in Buffer C containing 1 M NaCI, 
2~ mM Tris-HCl (pH 7.0), 0.3 M sucrose, 2mM DTT, and protease 
i~hibitors for 45 min in the presence or absence of 1 pM MBED for 
[3H]MBED binding and 10/tM ryanodine for [3H]ryanodine binding. 
[3pI]MBED binding reached a plateau within 30 min at 0°C. The 
amounts of both radio-ligands bound to microsomes or solubilized 
s;imples were determined by membrane filtration as previously de- 
s~ ribed [29]. 
cGMP-dependent protein kinase (PKG) was purified from bovine 
h!ng by the method of Lincoln [34]. Microsomes (1mg/ml) were incu- 
b tted with PKG (5 mg/ml) plus 1 mM ATP and 10 pM 8-bromo-cGMP 
f, ~r 30 min at 20°C in phosphorylation buffer (0.3 M sucrose, 1M NaCI, 
1) mM MgC12, 100 gM CaC1 z, 20 mM Tris-HC1, pH 7.4). After 20- 
t 'nes dilution with Buffer B, [3H]MBED and [3H]ryanodine binding 
v as assayed as described above. 
3, Resu l t s  
Fig. 1 shows a concentration-dependent inhibition of 
[ H]MBED binding by caffeine. [3H]MBED binding was nearly 
~bolished by 5 mM caffeine (Fig. 1A). Lineweaver-Burk plot 
~f the data indicates the IC50 value of 1 mM (Fig. IB). On the 
c,ther hand, the ICs0 value for replacement of bound 
[ H]MBED by non-labeled MBED was 0.18 pM. Therefore, 
[ H]MBED binds to the sites with about 5000 times higher 
~,ffinity than that of caffeine. Fig. 2 shows a saturation analysis 
~, nd a corresponding Scatchard analysis from a typical binding 
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~:ig. 1. Concentration-dependent inhibition of [3H]MBED binding by 
:affeine. (A) [3H]MBED to microsomes in the presence of various 
:oncentrations of caffeine were measured. (B) Lineweaver-Burk plot 
~f the data in (A). Microsomes were incubated with 50 nM [3H]MBED 
or 45 min at 0°C, as described insection 2. Specific binding was derived 
~)y subtracting non-specific binding determined in the presence of 
I gM unlabeled MBED. Results are representative from three experi- 
tnents. The amount of [3H]MBED binding in the absence of caffeine 
was 22 + 2.1 pmol/mg. The concentration f caffeine which reduced the 
amount of bound [3H]MBED to one-half the maximum value was 
l mM. 
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Fig. 2. Kinetical analysis of [3H]MBED binding to brain microsomes 
in the presence orabsence ofcaffeine. Microsomes were incubated with 
various concentrations of [3H]MBED (10-70 nM) in the presence or 
absence of caffeine for 45 min at 0°C, as described in Fig. 1. The 
caffeine concentrations were 0 (e), 0.3 (1) and 0.8 mM (&). Results are 
representative from three xperiments. Kd values for [3H]MBED in the 
presence of0.3 mM and 0.8 mM caffeine were 51 and 102 nM, respec- 
tively, and that in the absence of caffeine was 29 nM. Caffeine did not 
affect he Bmax value (34.5 pmol/mg). 
experiment, respectively. Specific binding was saturable and of 
high affinity. Values for Kd and Bmax were 29 nM and 34.5 
pmol/mg, respectively. Caffeine (0.3 and 0.8 mM) increased the 
Kd value for [3H]MBED from 29 to 51.3 and 102 nM, respec- 
tively, without affecting the Bmax value, indicating a competitive 
mode of interaction between [3H]MBED and caffeine at the 
same binding site. The specific binding of [3H]MBED com- 
pletely disappeared by treatment of the microsomes with tryp- 
sin (data not shown). These results suggest hat [3H]MBED 
binds to caffeine-binding sites in brain microsomes with higher 
affinity than that of caffeine and that the site is presumably 
formed with proteins. 
Fig. 3 shows the effects of various drugs on [3H]MBED 
binding. The [3H]MBED binding was stimulated by AMPPCP, 
an unhydrolyzable ATP-analog in a concentration-dependent 
manner (0.1 100 tiM), and reached apeak at 10/,tM AMPPCP. 
However, ryanodine and inositol 1,4,5-trisphosphate up to 10 
tiM did not affect the bluding. Procaine inhibited the binding 
with an ICs0 value of 1.1 mM, whereas Ruthenium red up to 
10 tiM failed to suppress the binding. [3H]MBED binding was 
not affected by Mg 2÷ up to 1 mM or Ca 2+ up to 0.1 mM. 
Adenosine receptor antagonists such as 8-cyclopentyl-l,3-di- 
methylxanthine and 3,7-dimethyl-l-propargylxanthine had no 
effect on the binding (data not shown). 
It is well known that plant-alkaloid ryanodine binds with 
high affinity to a receptor of SR in skeletal muscle [35-37]. 
Recently, ryanodine-binding sites have been demonstrated in 
brain [12-15]. The [3H]ryanodine binding to our microsomes 
was saturable and of high affinity and the values for Kd and Bma x 
were 13 nM and 240 fmol/mg, respectively. Although both of 
the K d values for [3H]ryanodine and [3H]MBED were almost he 
same, the Bm~ value for [3H]MBED was extremely larger than 
that for [3H]ryanodine (about 140 times). 
The distribution of [3H]MBED binding within the central 
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Fig. 3. Effects of various drugs on [3H]MBED binding to brain micro- 
somes. (A) Microsomes were incubated with 30 nM [3H]MBED in the 
presence of various concentrations of ryanodine (A), inositol-l,4,5- 
trisphosphate (0), Ruthenium red (t3), AMPPCP (I) or Ca 2+ (©). 
(B) Microsomes were incubated with 30 nM [aH]MBED in the presence 
of various concentrations ofprocaine (e) or Mg 2+ (©). Specific binding 
of [3H]MBED was measured as described as in Fig. 1. The amount of 
[3H]MBED bound to microsomes was expressed as percentages ofthat 
obtained in control experiment 07 pmol/mg). Results are representa- 
tive from three experiments. 
nervous system was investigated. Olfactory bulb, brainstem, 
cerebellum and hippocampus had 42 + 10.6, 87 + 7.8, 
113 + 12.1 and 135 + 9.4% binding of the whole brain. The 
highest binding was observed in cerebral cortex (148 + 6.2%). 
Brain microsomes were solubilized and fractionated by linear 
sucrose-density gradient centrifugation and the profiles of 
[3H]MBED and [3H]ryanodine binding activities of the 
fractions were shown in Fig. 4. Both profiles were different 
from each other. The peak of [3H]MBED binding activity (55% 
of the total binding activity) was found in fraction 6 and there 
was no [3H]ryanodine binding activity, whereas the peak of 
[3H]ryanodine binding activity (52% of the total binding ac- 
tivity) was found in fraction 8 and there was only 8% of the 
[3H]MBED binding activity. These results suggest hat caf- 
feine-binding proteins are different from ryanodine-binding 
proteins. 
PKG modulates [3H]ryanodine binding to cardiac muscle 
SR [38]. PKG may play also an important role in neuronal tis- 
sues [39,40]. Therefore, effects of PKG on both [3H]MBED 
and [3H]ryanodine binding were investigated (Table 1). Bind- 
ing of both was markedly suppressed by treatment of mic- 
rosomes with PKG in the presence of 8-bromo-cGMP 
and ATE [3H]MBED binding was not affected by ATP 
Table I 
Effect of cGMP-dependent phosphorylation on [3H]MBED and 
[3H]ryanodine binding to brain microsomes 
Control PKG 
MBED (pmol/mg) 8.58 + 0.42 1.83 + 0.06* 
Ryanodine (fmol/mg) 140 + 24 38.5 + 3.6* 
Brain microsomes were treated with PKG in the presence of ATP and 
8-bromo-cGMP for 30 min. Then, [3H]MBED and [3H]ryanodine bind- 
ing were assayed as described in section 2. 
*Significantly (P < 0.01) different from the control value. 
alone and/or 8Br-cGMP in the absence of PKG (data not 
shown). 
4. Discussion 
Caffeine has been extensively used as a pharmacological tool 
in various tissues including muscle and brain. However, the 
details of its binding sites are still unknown, because of its low 
affinity for binding. It has been reported that [3H]MBED shares 
the same binding site as that of caffeine in skeletal muscle SR 
[29]. In the present experiment we successfully demonstrated 
that [3H]MBED bound to proteins in brain microsomes with 
about 5000 times higher affinity than that of caffeine in 
a replaceable and saturable manner. [3H]MBED binding was 
almost completely inhibited by 5 mM caffeine. Kinetic anal- 
ysis indicates a competitive mode of interaction between 
[3H]MBED and caffeine. These results suggest hat even in 
neuronal tissue [3H]MBED shares the same binding site as that 
of caffeine but with extremely higher affinity than that of caf- 
feine. Therefore, [3H]MBED is an essential biochemical tool for 
characterization f caffeine-binding sites in mammalian brain 
at a molecular level. 
AMPPCP, the strongest stimulator of Ca 2+ release among 
adenine compounds, potentiated the [3H]MBED binding and 
procaine suppressed it,whereas ryanodine, Ruthenium red and 
divalent cations such as Ca 2÷ and Mg 2÷ did not affect 
[3H]MBED binding. These characteristics of [3H]MBED bind- 
ing sites in brain microsomes are quite similar to those in 
skeletal SR membrane [29]. Caffeine is known to affect IP 3 
receptors [13]. However, IP 3 did not affect [3H]MBED binding, 
and the Bm~ Xvalue for [3H]MBED in guinea pig brain is about 
400 times more than that for [3H]IP3 obtained in rat brain (0.098 
pmol/mg for [3H]IP3 [41] and 34.5 pmol/mg for [3H]MBED, 
respectively). Therefore, it is unlikely that [3H]MBED binds to 
IP 3 receptors. It is possible that caffeine and MBED bind to 
adenosine receptors in the plasma membrane because of their 
structural similarity to adenosine [1]. However, the Bm,x value 
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Fig. 4. Sucrose density-gradient centrifugation ofsolubilized brain mi- 
crosomes. CHAPS-solubilized microsomes (5mg) were fractionated by
linear sucrose density-gradient centrifugation as described in section 2. 
The amounts of [3H]MBED and [3H]ryanodine bound to each fraction 
were measured and expressed as percentage ofthose of the solubilized 
microsomes applied to the gradient. 
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for [3H]MBED in guinea pig brain is 90-200 times more than 
that for [3H]l,3-dipropyl-8-cyclopentylxanthine, an adenosine 
receptor antagonist, obtained in porcine brain (0.17~).40 pmol/ 
mg for [3H]l,3-dipropyl-8-cyclopentylxanthine [42]). Further- 
more, antagonists for Aj and A 2 subtypes of receptor did not 
al fect the binding of [3H]MBED. Therefore, it would seem that 
[31-I]MBED binds to major caffeine-binding proteins in brain 
rricrosomes but not to adenosine receptors. Interestingly, we 
h,tve recently found that MBED, like caffeine markedly stimu- 
l~tes locomotor activities of mice at a low dose (see Introduc- 
tim). Detailed investigation concerning the role of MBED 
b riding protein in the mechanism of its action on the central 
n ~'rvous ystem is underway. 
Recently, [3H]ryanodine binding sites have been demon- 
s rated in brain microsomes [24]. At least 3 subtypes of ryan- 
el ine receptors are expressed in brain. The amount of 
[ H]MBED binding sites is almost equal to that of [3H]ryan- 
e tine binding sites, suggesting that [3H]MBED binds to the 
r ,anodine receptor in skeletal SR membrane [29]. However, in 
t Le present experiment there is a serious discrepancy between 
t De amount of specific binding of [3H]MBED and that of [3H]ry- 
aaodine to brain microsomes (34.5 pmol/mg for [3H]MBED 
aad 240 fmol/mg for [3H]ryanodine). The distribution of 
[ H]MBED binding within the central nervous ystem distinct 
tom that for [3H]ryanodine binding in rabbit [13]. Binding of 
[ H]MBED but not [3H]ryanodine was enriched in the cerebral 
¢grtex in relation to the whole brain. Furthermore, judging 
tom the profile of both [3H]MBED and [3H]ryanodine binding 
t ) fractions of sucrose density-gradient centrifugation, 
[ H]MBED binding protein seems to be different from the ryan- 
dine receptor (Fig. 4). An attractive interpretation f all these 
, bservation is that [3H]MBED binds to a novel Ca 2÷ release 
t hannel or protein related to the channel in brain. However, the 
I ossibility that [3H]MBED binding protein represents ryan- 
dine receptor monomers which fail to bind [3H]ryanodine can- 
ot be excluded. 
The important role of PKG in neuronal tissues has been 
ecognized [39,40]. Elevation of cGMP level may prevent neu- 
', onal excitotoxicity by lowering the cytosolic alcium concen- 
~ ration. Addition of exogenous PKG with ATP and 8Br-cGMP 
,~ecreased both [3H]MBED and [3H]ryanodine binding. These 
esults suggest hat cGMP-dependent phosphorylation is in- 
olved in the regulation of the functions of major caffeine- 
finding proteins and Ca2+-release channels in neuronal tissues. 
t is consistent with the protection against he neuronal excito- 
oxity by cGMP. 
A physiological ligand for the activation of the CICR chan- 
lel (ryanodine receptor) is unknown except Ca 2+ in some tis- 
ues. A novel NAD ÷ metabolite, cyclic ADP-ribose has been 
eported as a candidate for such a role not only in sea urchin 
:gg cells but also in mammalian cells [43]. Relationship among 
ligands, i.e. cyclic ADP-ribose, caffeine and ryanodine re- 
nains to be elucidated, and further investigation should reveal 
he detailed mechanism of CICR and the action of caffeine in 
leural system. [3H]MBED will provide fruitful information 
~bout hem. 
In summary, [3H]MBED specifically binds to the major 
:affeine-binding protein in brain microsomes with extremely 
ligh affinity and becomes an essential biochemical tool to clar- 
fy the function of MBED/caffeine binding protein in neuronal 
dssues. 
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